Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants"

Infect Dis Ther. 2022 Aug;11(4):1757-1761. doi: 10.1007/s40121-022-00640-w. Epub 2022 May 16.

Authors

Jorge A Gomez¹, Javier Nieto Guevara², Josefina C Carlos³, Joanne A de Castro⁴, Donald Ray Josue⁵, Edwin Rodriguez⁵

Affiliations

¹ GlaxoSmithKline, Buenos Aires, Argentina. jorge.a.gomez-@gsk.com.
² GlaxoSmithKline, Panama City, Panama.
³ University of the East-Ramon Magsaysay Memorial Medical Center Incorporated, Manila, Philippines.
⁴ Department of Pediatrics, De La Salle Health Sciences Institute, Cavite, Philippines.
⁵ GlaxoSmithKline, Taguig, Philippines.

No abstract available

Keywords: Cost–benefit analysis; Immunization; Pediatric; Philippines; Pneumococcal conjugate vaccine; Pneumococcal disease; Pneumonia.

Publication types

Letter